MedPath

Ethris's Inhaled mRNA Therapy Shows Promise in Phase 1 Asthma Trial

Munich-based Ethris has reported positive Phase 1 results for ETH47, an inhaled mRNA therapy targeting uncontrolled asthma. The treatment demonstrated safety and tolerability across all dose levels in 40 healthy volunteers, successfully inducing targeted immune responses in the respiratory tract without systemic exposure.

Ethris, a Munich-based biotechnology company, has achieved a significant milestone in the development of messenger RNA (mRNA) therapeutics for respiratory conditions with positive Phase 1 results for its lead candidate ETH47, designed to treat uncontrolled asthma.
The clinical trial, which enrolled 40 healthy volunteers, demonstrated that the inhaled mRNA therapeutic was both safe and well-tolerated across all tested dose levels. Notably, no severe adverse events were reported, and no participants discontinued treatment during the study.

Novel Mechanism Targets Viral Triggers

ETH47 represents an innovative approach to treating uncontrolled asthma, a condition characterized by frequent and disruptive symptoms often triggered by viral infections. The therapy works by delivering mRNA that encodes interferon lambda (IFNλ), a protein crucial for maintaining antiviral immunity in the respiratory tract.
The study revealed a dose-dependent production of IFNλ in the nasal lining fluid, achieving the desired local immune response. Importantly, neither the mRNA therapeutic nor the produced IFNλ was detected systemically, supporting the company's strategy to minimize off-target effects through precise delivery to the respiratory tract.

Clinical Implications and Expert Insights

"These positive phase 1 results reinforce the promise of ETH47 as a potentially safe and transformative treatment option for asthma patients," stated Thomas Langenickel, Chief Medical Officer at Ethris. He emphasized that the results also validate their proprietary technology platform for delivering mRNA therapeutics to the respiratory tract.
The successful trial outcomes demonstrate the platform's capability to facilitate targeted protein production exactly where needed, marking a crucial advancement in respiratory mRNA therapeutics.

Development Pipeline and Future Plans

Building on these encouraging results, Ethris has announced plans to advance ETH47 into Phase 2a clinical trials in the second quarter of 2025. This next phase will specifically evaluate the therapy's effectiveness in asthma patients with rhinovirus infections.
Beyond ETH47, Ethris is leveraging its respiratory mRNA platform to develop treatments for rare genetic disorders. The company's pipeline includes protein replacement therapy candidates for conditions such as primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis (PAP), currently in discovery and preclinical stages.
The successful Phase 1 trial represents a significant step forward in the emerging field of inhaled mRNA therapeutics, potentially opening new avenues for treating various respiratory conditions with precise, locally-acting medications.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

ENA Respiratory's Novel Intranasal Antiviral Immune Enhancer Shows Promise in Phase Ib Trial

ENA Respiratory has successfully completed Phase Ib dosing of INNA-051 dry powder formulation in adults over 60, demonstrating good tolerability and activation of innate immune pathways. The new formulation offers improved stability with a two-year shelf life at room temperature, positioning it as a potential seasonal preventive treatment for viral respiratory infections.

Hoth Therapeutics' HT-001 Demonstrates 100% Success in Phase 2a Trial for Cancer Treatment Skin Toxicities

Hoth Therapeutics' HT-001 achieved a 100% success rate in a Phase 2a trial, significantly improving skin toxicities caused by EGFR inhibitors in cancer patients.
The CLEER-001 trial data showed that all patients achieved the primary efficacy endpoint, with notable improvements in skin toxicity by the six-week mark.

Alnylam's ALN-HTT02: First Patient Dosed in Phase 1 Huntington's Disease Trial

Alnylam Pharmaceuticals initiated a Phase 1 clinical trial for ALN-HTT02, a novel RNAi therapeutic targeting the huntingtin (HTT) gene for Huntington's disease (HD).
The trial aims to assess the safety and tolerability of ALN-HTT02 in up to 54 participants with Stage 2 or early Stage 3 HD, aged 25-70, across sites in the UK and Canada.

Tharimmune's TH104 Receives Positive EMA Feedback for Pruritus in Primary Biliary Cholangitis

Tharimmune received positive feedback from the EMA regarding its Phase 2 and Phase 3 clinical program for TH104, targeting moderate-to-severe pruritus in primary biliary cholangitis (PBC).
The EMA indicated that a hybrid application under Article 10(3) is acceptable, potentially allowing the use of existing non-clinical and safety data for TH104.

EMA Endorses Tharimmune's TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

The EMA has endorsed Tharimmune's TH104 clinical program for chronic pruritus in primary biliary cholangitis (PBC), supporting the company's development strategy.
The agency has accepted the Article 10(3) hybrid application, potentially streamlining the approval process by leveraging existing safety data.

MaaT Pharma Completes Enrollment in Phase 3 Trial of MaaT013 for Acute Graft-versus-Host Disease

MaaT Pharma has completed recruitment for its Phase 3 ARES trial evaluating MaaT013 in patients with steroid and ruxolitinib-refractory acute Graft-versus-Host Disease.
The ARES trial is a multicenter, European, open-label, single-arm study assessing the safety and efficacy of MaaT013, with topline results expected in January 2025.

Insignis Therapeutics' IN-001 Sublingual Epinephrine Spray Shows Positive Phase 1 Results for Anaphylaxis

Insignis Therapeutics' IN-001 demonstrated rapid epinephrine absorption, reaching a 100 pg/mL threshold in 9 minutes, offering a promising alternative to needle-based treatments.
The Phase 1 study showed sustained pharmacokinetics, with plasma epinephrine concentrations remaining above 100 pg/mL for 2 hours, ensuring a durable treatment effect.

Tectonic Therapeutic's TX45 Shows Promise in Phase Ia Trial for Pulmonary Hypertension

Tectonic Therapeutic reported positive topline data from its Phase Ia trial of TX45 for Group 2 pulmonary hypertension with preserved ejection fraction (PH-HFpEF).
The trial demonstrated that TX45 was safe and well-tolerated in healthy subjects, with minimal adverse events and no immune-mediated clearance observed.

Hoth Therapeutics Expands HT-001 Phase 2a Trial for EGFRi-Induced Skin Toxicities

Hoth Therapeutics has received IRB approval from Montefiore Medical Center and Dana-Farber Cancer Institute for its Phase 2a trial of HT-001.
The Phase 2a trial will assess the efficacy, safety, and tolerability of topical HT-001 for skin toxicities related to EGFR inhibitor treatments.

Evommune's EVO756 Enters Phase 2 Trial for Chronic Inducible Urticaria

Evommune has initiated a Phase 2 clinical trial for EVO756, a novel oral therapy targeting chronic inducible urticaria (CIndU).
The trial will evaluate EVO756's safety and efficacy in approximately 30 patients with symptomatic dermographism or cold urticaria across 15 US sites.

Reference News

[1]
Ethris reports positive phase 1 results for asthma mRNA therapy
outsourcing-pharma.com · Jan 30, 2025

Ethris reports positive phase 1 trial results for ETH47, an mRNA therapy targeting uncontrolled asthma by inducing an im...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy